A new arts and well-being program co-developed by the University of South Australia, Flinders University and the University ...

Researchers from the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), and NHG Health's ...

The Daily Mail launches a drive to defeat dementia after shocking statistics showed the disease is still the UK's biggest ...

Acadia Pharmaceuticals Inc. is rated a Buy for its steady NUPLAZID/DAYBUE franchises & pipeline-driven upside potential. Read ...

Bristol Myers jumps after choosing to continue its phase III ADEPT-2 study on Cobenfy for Alzheimer-related psychosis, delaying data to next year.

Bristol Myers will enroll more patients in its Cobenfy Alzheimer's psychosis study after site irregularities, with FDA-supported analysis suggesting encouraging early signals.

Study Continuation Follows Review of Site Level Data and Recommendation of Data Monitoring CommitteeBMS Remains Blinded to Study DataPRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY, ...

British neuroscientist Prof Ed Bullmore on how symptoms are not always obvious and why prevention is key to tackling the condition ...

On its own, LATE dementia is less severe than Alzheimer’s, but in combination, it makes Alzheimer’s symptoms worse, ...

Autoimmune encephalitis is a rare brain condition often mistaken for stress, fatigue, or dementia. It occurs when the immune ...

Exposure to high greenness levels is linked to decreased risk for hospital admissions for mental health disorders, especially ...

Chris Hemsworth’s new special explores the link between social connection and memory. But just how much can a bustling social ...